Marcus Vinicius Gomez

Dr. Marcus Vinicius Gomez

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2013 in Cancer Science
Verified
Journal Article
Open access
PDF file
FRFlavia Karine Rigo
Flavia Karine Rigo
GTGabriela Trevisan
Gabriela Trevisan
FRFernanda Rosa
Fernanda Rosa
GDGerusa D. Dalmolin
Gerusa D. Dalmolin
MOMichel Fleith Otuki
Michel Fleith Otuki
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez
The marine snail peptide ziconotide (ω‐conotoxin MVIIA) is used as an analgesic in cancer patients refractory to opioids, but may induce severe adverse effects. Animal venoms represent a rich source of novel drugs, so we investigated the analgesic effects and the side‐effects of spider peptide Phα1β in a model of cancer pain in mice with or without tolerance to morphine analgesia. Cancer pain was induced by the inoculation of melanoma B16‐F10 cells into the hind paw of C57BL/6 mice. After 14 days, painful hypersensitivity was detected and Phα1β or ω‐conotoxin MVIIA (10–100 pmol/site) was intrathecally injected to evaluate the development of antinociception and side‐effects in control and morphine‐tolerant mice. The treatment with Phα1β or ω‐conotoxin MVIIA fully reversed cancer‐related painful hypersensitivity, with long‐lasting results, at effective doses 50% of 48 (32–72) or 33 (21–53) pmol/site, respectively. Phα1β produced only mild adverse effects, whereas ω‐conotoxin MVIIA induced dose‐related side‐effects in mice at analgesic doses (estimated toxic dose 50% of 30 pmol/site). In addition, we observed that Phα1β was capable of controlling cancer‐related pain even in mice tolerant to morphine antinociception (100% of inhibition) and was able to partially restore morphine analgesia in such animals (56 ± 5% of inhibition). In this study, Phα1β was as efficacious as ω‐conotoxin MVIIA in inducing analgesia in a model of cancer pain without producing severe adverse effects or losing efficacy in opioid‐tolerant mice, indicating that Phα1β has a good profile for the treatment of cancer pain in patients.

7 August 2012 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
ASAlessandra Hubner de Souza
Alessandra Hubner de Souza
CCCélio J. Castro
Célio J. Castro
FRFlavia Karine Rigo
Flavia Karine Rigo
SOSara Marchesan Oliveira
Sara Marchesan Oliveira
RGRenato Santiago Gomez
Renato Santiago Gomez
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez

1 June 2014 in The Journal of Pain
Verified
Journal Article
Closed access
RTRaquel Tonello
Raquel Tonello
FRFlávia Rigo
Flávia Rigo
CGCamila Gewehr
Camila Gewehr
GTGabriela Trevisan
Gabriela Trevisan
EPElizete Maria Rita Pereira
Elizete Maria Rita Pereira
JFJuliano Ferreira
Juliano Ferreira

1 April 2014 in Toxicon
Verified
Journal Article
Closed access
ASAlessandra Hubner de Souza
Alessandra Hubner de Souza
ALAírton Martins da Costa Lopes
Aírton Martins da Costa Lopes
CCCélio J. Castro
Célio J. Castro
EPElizete Maria Rita Pereira
Elizete Maria Rita Pereira
CKCaroline Peres Klein
Caroline Peres Klein
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez

1 November 2014 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
DDDanuza Montijo Diniz
Danuza Montijo Diniz
ASAlessandra Hubner de Souza
Alessandra Hubner de Souza
EPElizete Maria Rita Pereira
Elizete Maria Rita Pereira
JSJuliana Figueira da Silva
Juliana Figueira da Silva
FRFlavia Karine Rigo
Flavia Karine Rigo
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez

Verified
Journal Article
Open access
PDF file
TATasmin Antunes
Tasmin Antunes
MCMaria Campos
Maria Campos
VCVanice Paula Ricardo Carvalho
Vanice Paula Ricardo Carvalho
CJClaudio Antonio da Silva Junior
Claudio Antonio da Silva Junior
LMLuiz Alexandre Viana Magno
Luiz Alexandre Viana Magno
MGMarcus Vinicius Gomez
Marcus Vinicius Gomez
Voltage-gated calcium channels (VGCCs) are targeted to treat pain conditions. Since the discovery of their relation to pain processing control, they are investigated to find new strategies for better pain control. This review provides an overview of naturally based and synthetic VGCC blockers, highlighting new evidence on the development of drugs focusing on the VGCC subtypes as well as mixed targets with pre-clinical and clinical analgesic effects.